Heartware closes oversubscribed
Thursday, 27 January, 2005
US artificial heart firm Heartware expects to have a market capitalisation of AUD$76.42 million when it lists on the ASX on Monday, having raised US$24.95 million (AUD$32.42 million) in an oversubscribed initial public offering.
The offer incorporates an AUD$5 million US private placement together with an Australian public offer at $0.50 per share.
Heartware is currently preparing a response to a lawsuit issued by Sydney artificial heart firm Ventracor (ASX:VCR) late last year alleging that Heartware's device infringed on the patents underlying Ventracor's ventricular assist device. The response is due by Feburary 7.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
